Advanced glycobiology-based therapies for the treatment of cancer and infectious diseases

This is an area of research that has seen a significant increase in interest over the last five years from the pharmaceutical sector and offers fantastic opportunities for translating results into clinical practice. The main objectives of this project are:

Development of immune checkpoint inhibitors targeting DC-SIGN based on an N-glycan base structure.

 Development and evaluation of new Siglec-10 antagonists designed around an extended lactosamine pharmacophore.

 Chemical synthesis and methodological improvement to obtain glycans from natural sources.

 Synthesis of glycan nanoparticles functionalised with glucans as glycoconjugate vaccines.

 Research into cutaneous therapy via targeted administration of glycan nanoparticles to Langerhans cells.

 Glycan nanoparticles based on VLPs as anti-adhesive inhibitors of bacteria and viruses.

 Study of serum glycans with lectin microarrays as personalised cancer markers and ageing markers.